Authorized Generics Under Scrutiny By The FTC

Law360, New York (March 31, 2006, 12:00 AM EST) -- With the debate over authorized generics heating up in recent months, this week’s move by the Federal Trade Commission to determine whether the practice violates anticompetitive guidelines could have wide-ranging effects on the pharmaceutical industry, experts say.

Among the largest generic drug makers slated for FTC scrutiny are Andrx Corp. and Teva Pharmaceutical Industries Ltd., both of which have recently been engaged in high-profile battles with brand-name companies over authorized generics.

Teva’s role in the probe may be especially significant in light of the company’s $7.4...
To view the full article, register now.